Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial

IMPORTANCE: About 1% of children and adolescents worldwide are affected by plaque psoriasis. OBJECTIVE: To evaluate the long-term efficacy and safety of ixekizumab for pediatric patients with moderate to severe psoriasis. DESIGN, SETTING, AND PARTICIPANTS: This multicenter randomized clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Paller, Amy S., Seyger, Marieke M. B., Magariños, Gabriel A., Pinter, Andreas, Cather, Jennifer C., Rodriguez-Capriles, Claudia, Zhu, Danting, Somani, Najwa, Garrelts, Alyssa, Papp, Kim A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008559/
https://www.ncbi.nlm.nih.gov/pubmed/35416908
http://dx.doi.org/10.1001/jamadermatol.2022.0655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008559/
https://www.ncbi.nlm.nih.gov/pubmed/35416908
http://dx.doi.org/10.1001/jamadermatol.2022.0655

Ejemplares similares